Nicosia, Cyprus. A Cyprus-based research-to-market team developing the M³Phantom medical imaging system has outlined its progress and commercial ambitions. The project is supported by the non-profit organisation Cyprus Seeds.
Project and team structure
The project, known as the M³Phantom or Modular Motion Medical Phantom, is led by a multidisciplinary team combining expertise in medical imaging, engineering, intellectual property, operations and commercialisation strategy.
The team is headed by professor Yiannis Parpottas, chief executive officer, who has coordinated major development work on the system.
Technical leadership is provided by Dr George Charitou, chief technology officer, who supports system upgrades and oversees operations in major hospitals in Cyprus.
Commercialisation and intellectual property strategy is led by Panagiotis Mousikos, chief commercialisation and IP officer, while Dr Athanasia Tzortzi, chief operations officer, focuses on communication and marketing strategy.
The engineering dimension is strengthened by professor Antonis Lontos, who contributes expertise in manufacturing engineering.
System purpose and intended impact
The M³Phantom system is described as a next generation medical imaging phantom designed to simulate real patient movement and disease conditions.
By replicating realistic physiological motion, the system aims to improve diagnostic accuracy and clinical decision confidence in medical imaging.
The team said its solution enhances imaging quality by enabling more realistic testing environments for radiology and nuclear medicine systems.
Recent milestones
Over the past 12 months, the project has achieved three major milestones across commercial, technical and validation domains.
What developments will you be looking for next as the M³Phantom project moves toward commercialisation?